home | contact
Finding safer, more effective treatment for opioid-induced bowel dysfunction, addiction and overdose.
Aiko's patented portfolio of compounds includes naltrexone / naloxone analogs, including naltrexol, naltrexamine and naloxol derivatives. Each compound has been demonstrated to display neutral antagonist properties at the mu opioid receptor.


AIKO-150 is the only known candidate drug suitable for co-formulation with an opioid analgesic that will confer both abuse resistance and limited side effects, particularly constipation.



AIKO Biotechnology steps back to reformulate, seek financing



The effects of the opiate neutral antagonist 6β-naltrexol in opiate dependent subjects
6βN acts as a neutral opiate antagonist, is less potent than naloxone in precipitating OWD and produces laxation.


AIKO Biotechnology, Inc. | 2 Union Street | Suite 501 | Portland, ME 04101